Preliminary results from a study combining TLR9 agonist SD-101 with pembrolizumab showed increased chemokine levels and tumor responses, indicating partially overcome tolerance with manageable hepatotoxicity [74]. This evidence concerns the gene TLR9 and neoplasm.